Jessie, it looks like we are in agreement on how PPHM has enough time to finish a Phase 3 trial under the loan terms.
Regarding your cost call outs, consider that your cost of development stats need to place PPHM at the FDA trial design discussion phase, since Phase 2 is wrapping up. PPHM isn't starting from zero here.
Much of that cost you reference for commercialization has already passed the Bavi development track. PPHM managed to leverage Avid as their in house source of trial product and did other things to keep the cost down. If PPHM decides to go it alone, there will need to be trial results reported combined with uncooperative Pharma partner prospects. At this point, PPHM would need maybe $25 million plus operational funding to keep the rest of their business viable to go it alone on Phase 3. yes indeed. PPHM is ready to launch a Bavi Phase 3 trial if the FDA so approves.
One thought that has come to my mind is that those bankers who wrote that loan enabling two $15 million funding tranches might be persuaded to fund a Phase 3 trial in exchange for ???
Best wishes and IMO.
KT
Market Data 
Markets 
AI
